Member Info for AquaeSulis01

Opp-H thanks for the link which confirms expiry date 15/02 rather than 18/02 (aired on side of caution from re-listing date 18th Feb 2019)

Confirm totals that had the 15/02 expiry date are as follows:

28/01/19 Refinancing Business £1M 200,000,000 1
SI Capital Limited  2,500,000 1
SP Angel Limited 2,500,000 1
Mr Brian Moritz, a former non-executive director 6,000000 0.5

Link to the Seneca B half year accounts where Skin is one of only two quoted (as opposed to unquoted) investments (the other being optibiotix) in their Portfolio B holdings and their largest carrying value when the share price was 16.75p (commentary reads "The period also saw an increase in the bid price of the B share pool’s remaining AIM quoted investments: the SkinBioTherapeutics Plc share price increased to 16.75p as at 30 June 2020 (from 14p as at 31 December 2019) and the OptiBiotix share price increased to 49p as at 30 June 2020 (compared to a cost price of 40p per share).

Consequently, no surprise to see them re-balancing their portfolio with the recent sell off; it is their policy and their Outlook section actually states "We are pleased that Seneca have developed a spread of B share portfolio investee companies, some of which are unquoted and some of which are AIM quoted, thereby reducing concentration risk for the Company’s B shareholders in relation to any one single investment; the Board and Seneca remain acutely aware of the need to continue to work at close quarters with all B share portfolio investee companies as they navigate the challenges ahead."

Incidentally, any Opti investor displeased that Opti are now proposing to include Skin in the profit/loss column of their consolidated accounts should ask themselves why it wasn't properly recorded in the accounts from the outset instead. Check how Seneca account for Skin etc in just that way.

https://www.lse.co.uk/rns/SVCT/half-year-report-s2d5n2f10stgn8n.html

Despite Opti owning > 20% of skinbio which would enable the asset to be recorded in the accounts as "An Investment in an Associate" because of the degree of influence they could bring to bear on future skinbio decisions, I suspect they will maintain a hands off approach and hence account for skinbio as a Gain on investments held at fair value in the Condensed Consolidated Statement of Comprehensive Income part of the accounts and hence a contributor to profits. This is standard accounting practice; have a look at Allied Minds accounts as an example.

skid I agree from a business perspective, opti must and are focused on the management of the company. However, if opti announced tomorrow that they had agreed a price to sell their holding in skinbio and intended to return the proceeds as a dividend to shareholders, do you not see the Opti sp rising significantly above today's sp?

anon, you cannot ignore the 24% holding in skinbio which positions Opti as an IP commercialisation company (for someone like Allied Minds it's their sole business) in addition to the divisions that they directly manage. It is too valuable to ignore

From the 28th Jan 2019 RNS
§ Conditional placing and subscription (the "Refinancing") raising £1,000,000 at a price of 0.5 pence per new ordinary share, resulting in the issue of 200,000,000 new ordinary shares of 0.1 pence each, (the "Refinancing Shares");
§ The Refinancing of the Company is subject to the passing of all resolutions at a General Meeting to be held by the Company, (the "General Meeting") (further details of which are set out below), the resumption to trading in the Company securities on AIM and the admission of to trading on AIM of the Refinancing Shares, Creditor Shares, Fee Shares and Director Shares ("Admission");
§ Each Refinancing Share has an attaching warrant to subscribe for a new ordinary share of 0.1 pence each in the Company, ("New Ordinary Shares"), at a price of 1 pence per share with a two-year life to expiry (the "Refinancing Warrants") from the date of Admission;
§ The refinancing exercise will allow payment of all material Company creditors through a mixture of cash and/or shares and enable the Company to be essentially debt free with a robust cash position sufficient for at least 12 months of operation when considering current business costs and operational plans;
§ Subject to the passing of resolutions at the General Meeting and the conditions detailed below, Roger Murphy, CEO and Matt Wood, Executive Director to step down from the board with Andrew Bell to be appointed Executive Chairman and Paul Johnson as Executive Director;
§ Andrew Bell and Paul Johnson (or their connected parties) have committed to subscribe for £50,000 each in the Refinancing on the terms as outlined above. Additionally, Red Rock Resources, a company of which Andrew Bell is a director, has committed to subscribe for £100,000 in the Refinancing
Subsequently on Feb 15th 2019:
African Battery Metals plc, the AIM quoted African focused exploration company, announces that at its General Meeting held earlier today, Friday 15th February 2019, all Resolutions were duly passed by the Company's shareholders. Following completion of the General meeting the Company has requested that trading in its shares resumes on AIM at 7:30 a.m. on 18 February 2019.

Two years having passed, unless there are late warrant exercised notifications, I presume that the 51,228,000 warrants o/s have now expired, and that as there has been no announcement of director's exercising warrant options that PJ and Andrew Bell have generously allowed their 10,000,000 collective warrants options to lapse (suspect the addition 10,000,000 warrants attributed to RRR via Andrew Bell will have been exercised and no requirement to declare).

Zeon, IIs such as Seneca invest in growth rather than value companies, and despite their recent profit take and reduction in their Skinbio holding, it remains the biggest % holding in their B Class Share portfolio. Now if they continue to reduce their interest and no other Growth ii company steps in to replace them, then in the short term you will no doubt be able to buy in lower, however, trying to judge the bottom and buy at exactly the right time is a fruitless quest, and through experience I have learnt to take a slightly longer term view and if I judge the share price will be at a much higher level in the not too distant future, I buy, add and hold. Each to their own and good luck

Skid/Belgrano, agree consistency and clarity is required across reporting statements, and Skinbio should be an asset on the balance sheet, is not factored into the current share price, making the current price a huge buy as disappointing news was already factored into a share price in the low 60s let alone 50s

Admiral, 51,228,000 warrants will shortly expire if not in the process of being taken up, but there remain 141,513,161 o/s 0.75p warrants and72,500,000 o/s 0.70 warrants with later expiry dates that are regularly being exercised.

Hmm, disappointing RNS compared to what was expected. The half year statement indicated each division would be profitable, however, the consumer health division operated at a loss. Also, at the half year stage, Stephen O'Hara, CEO of OptiBiotix, commented: "This has been another period of exciting progress for OptiBiotix with a 400% increase in sales and a large reduction in costs compared to the same period last year, so a disappointing second half that resulted in 400% reducing to 103% for the year as a whole.
"Total invoiced sales for the Group were £1,513,089 (2019: £744,833), an increase of 103% on the previous year."

No-one has mentioned the most exciting part concerning the additional 65 volunteers, and something that has not been priced in; "The increased size of the study allows us to widen our scope to assess the impact of AxisBiotix-Ps on the symptoms of other skin conditions beyond psoriasis; this is an exciting scope of research that will run concurrently with the primary trajectory of AxisBiotix-Ps."

That is not what the RNS said, the royalties that are due in 2024 are visible now.

"On the supply side of our SteelCell® ecosystem we announced the scale up to an aggregate 250MW of manufacturing capacity for 2024, giving us visibility of high margin royalty revenues."

Agree great numbers and nice to see the absence of the word "pending" inferring that that the Weichai Bus trial has been successful and by default the Ceres Technology validated. "Ceres and Weichai intend to establish a joint venture in mid-2021, following the successful conclusion of the bus trial"

Wording from the interims read "Having successfully developed a world-first 30kW solid oxide fuel cell ("SOFC") prototype range extender for electric city buses running on compressed natural gas, the team moved on to the second iteration of the design at the end of 2019. This is currently being built into a fleet of five buses which are undergoing trials in China. There were some delays to the project in the early part of 2020 due to the pandemic which will delay completion of these trials by up to six months, but Weichai's SOFC team with support from Ceres has been back at full capacity for some time and good progress is now being made to validate the Ceres technology for automotive applications."

It's called potential fitzy, and depends on your definition of close. For me big bucks arriving by the end of this year via 2 disruptive products with spin-offs to address acne etc plus 3 other products lined up for commercialisation in the pipeline, makes this company under rather than over valued in the circumstances; IT IS A GROWTH rather than a VALUE company!

As exploration to date supports Molopo Farms being made up of dyke like feeder bodies rather than laterally extensive PGE mineralization, worth watching the short media clip put up by Kavango Resources to explain how Large Scale Metal Sulphide Deposits are formed in the Kalahari Suture Zone as the geology appears very similar.

https://twitter.com/KavangoRes?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

elric you do yourself no favours getting drawn into a debate with someone who offers no novel or valuable reposte. Raise above it and filter rather than respond

Might need to access the podcast via this link (FTG Gravity Podcast)

https://www.bellgeo.com/resources

From the Molopa Farms RNS "The collaboration with Bell will facilitate the integration and analysis of the KKME airborne and ground geophysical data with Bell's high-resolution Zeppelin airship-supported gravity data collected over the three KKME Molopo Farms Complex licence areas (PL202/2018, PL310/2016, PL 311/2016). "

Worth a watch of the Bell PBE podcast at 1-16-15 and 1-39-07 where Botswana work done for De-Boers is discussed. The predictive techniques to refine and predict the precise location of new targets loks very exciting

https://www.youtube.com/watch?v=ulYU9HurEWU&feature=emb_logo

I see Rainbow Rare Earth has just reported very good assay results from their project following samples sent circa Jan 7th to a South African lab for testing and returned and announced today; approx 5 week lead time. So using that lead time as a rough guide , I guess we may well hear about Molopo Farm assay results circa 23rd Feb and Haneti circa first week in March.

Well worth a watch

https://www.sharesmagazine.co.uk/video/strix-group-ketl-mark-bartlett-ceo-2